Topic

aging-research

3 articles on aging-research in longevity medicine. View all news →

Sex-specific longitudinal reversal of aging in old frail mice

Oxytocin plus ALK5 Inhibition in Old Mice: What 73% Means

A late-life oxytocin and ALK5-inhibitor experiment extended remaining survival in male mice, but not females. Here is what the 73% result does and does not mean.

oxytocin TGF-beta aging-research
ARPA-H PROSPR program

ARPA-H PROSPR and VITAL-H: What the Registered Healthspan Trial Tests

VITAL-H is registered as a phase 2 trial of semaglutide, dapagliflozin and placebo, with no results yet. How that differs from the PROSPR announcement and what longevity clinics cannot claim.

UT Health San Antonio

UT Health Rapamycin Study: Three Sub-Studies, Two Timelines, and No Results Yet

UT Health San Antonio described a multi-phase rapamycin project and a separate short recruitment study. Here is what each protocol tests, what remains unknown, and what the announcement does not prove.

rapamycin mTOR inhibitors clinical trials